Metformin in Patients With Unruptured Vertebrobasilar Dissecting Aneurysms (METTLE)

Exclusion Criteria

• •1. Patients with aneurysms located in non-vertebral basilar artery sites (mainly referring to bifurcation saccular aneurysms);
• •2. Patients with combined diabetes or its complications;
• •3. Patients who are allergic to any components in MET;
• •4. Pregnant and lactating female patients;
• •5. Patients with other immune diseases in combination, patients taking immunosuppressants or anti-inflammatory drugs (such as long-term use of aspirin, statin, hormones and other drugs);
• •6. Target aneurysm-related symptoms were severe at the time of diagnosis, and the mRS score was ≥3;
• •7. VBDAs have received interventional or surgical treatment;
• •8. Those with severe allergy to the contrast agent gadolinium terlumate glucosamine (Gd-DTPA) (skin rash not counted);
• •9. Those with severe renal disease resulting in renal insufficiency (glomerular filtration rate \<30ml/(min·1.73m2));
• •10. Patients with metal implants in the body (e.g., cardiac stents, cardiac prosthetic valves, pacemakers, metal joints, steel plates, non-removable metal dentures, etc.);
• •11. Patients known to suffer from dementia or psychiatric disorders and claustrophobia who are unable to complete the magnetic resonance examination;
• •12. Patients with other serious diseases combined at the time of diagnosis and with an expected survival time of less than 1 year;
• •13. Patients who are participating in clinical trials of other drugs or devices.
• •14. Other conditions judged by the investigator to exist that are unsuitable for enrollment.